Wednesday, October 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Maintains Negative Stance on Intel NASDAQ INTC with 17 Price Target

Elaine Mendonca by Elaine Mendonca
January 27, 2024
in Breaking News
0
Technology Cloud computing Trading online
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

On January 27, 2024, Hans Mosesmann, an analyst at Rosenblatt, once again voiced his negative sentiment towards Intel (NASDAQ: INTC) by reiterating his “Sell” recommendation and maintaining a price target of $17. This unwavering stance from Mosesmann reflects his persisting skepticism regarding the company’s performance. The report released on January 26, 2024, further reinforces the prevailing bearish outlook for Intel’s stock.

INTC Stock Plummets: Factors Behind the Significant Drop on January 27, 2024

INTC Stock Experiences a Significant Drop on January 27, 2024

On January 27, 2024, Intel Corporation (INTC) stock experienced a significant drop in its value, causing concern among investors. The stock, which had been trading near the top of its 52-week range and above its 200-day simple moving average, took a sudden turn for the worse.

According to data from CNN Money, the price of INTC shares decreased by $5.90 since the market last closed, resulting in an 11.91% drop. This decline is quite substantial and raises questions about the factors contributing to such a significant decrease in value.

Closing at $43.65, INTC stock initially seemed to be performing well. However, the after-hours trading saw a further decline of $0.03, indicating that the downward trend might continue in the coming days.

One potential factor contributing to this drop in stock value could be related to Intel’s overall performance as a company. If there were any negative news or developments in their business operations, it could have had a direct impact on the stock price. Investors may want to investigate any recent announcements or reports from Intel to gain a better understanding of the situation.

Furthermore, broader market conditions and industry trends could also have played a role in INTC’s decline. If there were any negative sentiments or concerns regarding the semiconductor industry or the technology sector as a whole, it could have affected investor confidence in Intel and led to a sell-off of its shares.

Investors should also consider the possibility of market manipulation or external factors that could have influenced the stock’s performance on January 27, 2024. It is crucial to conduct a thorough analysis and gather additional information to make informed investment decisions.

While the drop in INTC stock’s value is undoubtedly concerning, it is important to remember that stock prices can be volatile, and fluctuations are a normal part of the market. Investors should avoid making impulsive decisions based solely on short-term price movements and instead focus on the long-term prospects of the company.

It is advisable for investors to consult with financial advisors or conduct their own research to gain a comprehensive understanding of the situation before making any investment decisions related to INTC or any other stocks.

INTC Stock Performance: Mixed Results on January 27, 2024 – Intel Corporations Path to Recovery

Title: INTC Stock Performance: A Mixed Bag on January 27, 2024

Introduction:

On January 27, 2024, Intel Corporation (INTC) witnessed a day of mixed stock performances. The company’s financial data reveals a decline in total revenue and net income compared to the previous year. However, there was a slight increase in revenue and a flat net income compared to the previous quarter. Furthermore, the earnings per share remained unchanged since the last quarter but experienced a significant decrease compared to the previous year.

Total Revenue:

Intel’s total revenue for the past year amounted to $54.23 billion, representing a 14.0% decrease compared to the previous year’s revenue. However, when compared to the previous quarter, the company experienced an 8.81% increase in total revenue, reaching $15.41 billion.

Net Income:

The net income for Intel Corporation stood at $1.69 billion for the past year, indicating a substantial decline of 78.92% compared to the previous year’s net income. However, when compared to the previous quarter, the net income remained flat at $2.67 billion.

Earnings per Share:

Intel’s earnings per share (EPS) for the past year amounted to $0.40, representing a significant decrease of 79.38% compared to the previous year’s EPS. However, similar to the net income, the EPS held flat at $0.63 since the previous quarter.

Analysis:

The stock performance of Intel Corporation on January 27, 2024, showcases a mixed bag of results. While the company experienced a decline in total revenue, net income, and earnings per share compared to the previous year, there was a slight improvement in revenue and stability in net income and EPS when compared to the previous quarter. These figures suggest that Intel is taking steps towards recovery and stabilizing its financials.

Conclusion:

Intel Corporation’s stock performance on January 27, 2024, showcased a mixed bag of results. While the company witnessed a decline in total revenue, net income, and earnings per share compared to the previous year, there was a slight improvement in revenue and stability in net income and EPS since the previous quarter. These figures indicate that Intel is making efforts to stabilize its financials and regain its position in the market. Investors should closely monitor the company’s future financial reports to assess its progress and potential for growth.

Tags: INTC
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Film and camera

First Citizens BancShares Strong Financial Performance and Dividend Declaration Instill Investor Confidence

Solar panel

Biden Administration Temporarily Halts Approval of LNG Exports to Assess Environmental and Energy Impacts

Cryptocurrency Market Capitalization

Analysis of Options Trading Trends and Price Target for Upstart Hldgs

Recommended

Pharmaceutical Markets and money

Mixed Results from PL9643 MELODY1 Phase 3 Clinical Trial for Dry Eye Disease

2 years ago
ALB stock news

Gallagher Benefit Services Inc. Makes Bold Investment in Donaldson Company, Inc.

2 years ago
Vertiv Stock

Vertiv Stock: Strong Fundamentals Defy Market Pessimism

2 months ago
Finance_Financialization

Analyst Maintains Market Perform Rating and Raises Price Target for SmartFinancial

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Rigetti Shares Plunge as Valuation Concerns Mount

Under Armour Shares Plummet as Analyst Pessimism Deepens

Tech Sector at Crossroads as M&A Buzz Battles Profit-Taking

Meta’s AI Ambitions Fuel Bullish Outlook Ahead of Earnings

Can Wolfspeed Capitalize on Its Financial Rebirth?

UnitedHealth Faces Legal and Technological Crossroads

Trending

Sarepta Therapeutics Stock
Analysis

Sarepta Therapeutics: Institutional Bets and Clinical Breakthroughs Fuel Optimism

by Dieter Jaworski
October 22, 2025
0

Institutional investors are demonstrating significant confidence in Sarepta Therapeutics through recent strategic moves. Privium Fund Management B.V....

Affirm Holdings Stock

Affirm Stock: Strategic Moves Position BNPL Leader for Critical Holiday Season

October 22, 2025
Arrowhead Stock

Arrowhead Pharmaceuticals: A Biotech Contender’s Strategic Ascent

October 22, 2025
Rigetti Computing Stock

Rigetti Shares Plunge as Valuation Concerns Mount

October 22, 2025
Under Armour Stock

Under Armour Shares Plummet as Analyst Pessimism Deepens

October 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Sarepta Therapeutics: Institutional Bets and Clinical Breakthroughs Fuel Optimism
  • Affirm Stock: Strategic Moves Position BNPL Leader for Critical Holiday Season
  • Arrowhead Pharmaceuticals: A Biotech Contender’s Strategic Ascent

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com